In the relatively near future, there may be additional PET radiotracers based on gastrin-releasing peptide receptor and fibroblast activation protein which may provide synergism to PSMA PET or have utility in those prostate cancers that express no or low PSMA expression [19]. This evidence concerns the gene FOLH1 and prostate cancer.